Latest & greatest articles for fenofibrate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fenofibrate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fenofibrate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fenofibrate

1. Fenofibrate

Fenofibrate Top results for fenofibrate - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for fenofibrate The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

2. Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes Mellitus

Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes Mellitus 29472432 2018 02 23 1935-5548 2018 Feb 22 Diabetes care Diabetes Care Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes Mellitus. dc170968 10.2337/dc17-0968 In clinical trials, treatment with fenofibrate did not reduce the incidence of major cardiovascular events (MCVE) in patients with type 2 diabetes mellitus (T2DM). However (...) , treatment effects reported by trials comprise patients who respond poorly and patients who respond well to fenofibrate. Our aim was to use statistical modeling to estimate the expected treatment effect of fenofibrate for individual patients with T2DM. To estimate individual risk, the FIELD risk model, with 5-year MCVE as primary outcome, was externally validated in T2DM patients from ACCORD and the SMART observational cohort. Fenofibrate treatment effect was estimated in 17,142 T2DM patients from FIELD

EvidenceUpdates2018

3. FIELD Substudy: Fenofibrate in Patients with Diabetes, by Gender

FIELD Substudy: Fenofibrate in Patients with Diabetes, by Gender RxFiles Trial Summary A Crawley, L Regier - Feb 2015 FIELD Substudy: Fenofibrate in Patients with Diabetes, by Gender 1 Fenofibrate Intervention and Event Lowering in Diabetes BOTTOM LINE At face value the article suggests that fenofibrate LIPIDIL should be prescribed for females with diabetes, high TGs, and low HDL. However, there are a number of factors that would warrant not adopting this as routine practice. 1) Note (...) mortality in those at high CV risk, including those with diabetes. Statins have consistently demonstrated more benefit than harm. On a somewhat related note, the ACCORD-Lipid trial found that fenofibrate failed to show additional benefit in someone with T2DM already on statin therapy. If one wants to lower CV risk in a female with diabetes, a statin would still have evidence supporting a first line role. Fenofibrate would be reasonable in a female with T2DM who was unable to take a statin, or in whom

RxFiles2016

4. Lipanthyl (fenofibrate) - hypertriglyceridaemia or hyperlipidaemia

Lipanthyl (fenofibrate) - hypertriglyceridaemia or hyperlipidaemia HAS - Medical, Economic and Public Health Assessment Division 1/11 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 22 January 2014 LIPANTHYL 67 mg micronised, capsule B/60 (CIP 335 271-6) B/90 (CIP 335 272-2) LIPANTHYL 145 mg, film-coated tablet B/30 (CIP 369 641-0) B/90 (CIP 369 642-7) LIPANTHYL 160 mg, film-coated tablet B/30 (CIP 355 373-9) B/90 (...) (CIP 371 780-4) LIPANTHYL 200 mg micronised, capsule B/30 (CIP 332 635-7) B/90 (CIP 371 785-6) FENOFIBRATE FOURNIER 100 mg, capsule B/30 (CIP 362 756-7) FENOFIBRATE FOURNIER 300 mg, capsule B/30 (CIP 361 735-6) SECALIP 100 mg, capsule B/48 (CIP 323 764-2) SECALIP 300 mg, capsule B/30 (CIP 330 030-0) Applicant: ABBOTT PRODUCTS SAS INN fenofibrate ATC Code (2010): C10AB05 (Lipid modifying agents, plain - fibrates) Reason for the review Renewal of inclusion Extension of indication List concerned

Haute Autorite de sante2014

5. Cholib - fenofibrate / simvastatin

Cholib - fenofibrate / simvastatin 27 June 2013 EMA/CHMP/308856/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Cholib International non-proprietary name: fenofibrate / simvastatine Procedure No. EMEA/H/C/002559/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile (...) BE Bioequivalence BLQ Below Limit of Quantification BMI Body Mass Index CHD Coronary Heart Disease CHF Congestive Heart Failure CI Confidence interval Cmax Maximal concentration CRP C-Reactive Protein CV Cardiovascular CVD Cardiovascular Disease CYP Cytochrome P DEHP di(2-ethylhexyl) phthalate eGFR Estimated Glomerular Filtration Rate FA Fenofibric acid FDC Fixed Dose Combination FIELD (study) Fenofibrate Intervention and Event Lowering in Diabetes FXR Farnesoid X Receptor GI Gastro intestinal HDL-C High

European Medicines Agency - EPARs2013

6. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study

Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study 22210576 2012 01 25 2012 06 12 2015 01 29 1935-5548 35 2 2012 Feb Diabetes care Diabetes Care Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. 218-25 10.2337/dc11-1109 Diabetic patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] 30-59 mL/min/1.73 m(2)) are at particular (...) cardiovascular risk. Fenofibrate's safety in these patients is an issue because it may elevate plasma creatinine. Furthermore, guidelines regarding fenofibrate dosing in renal impairment vary internationally. We investigated fenofibrate's effects on cardiovascular and end-stage renal disease (ESRD) events, according to eGFR, in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Type 2 diabetic patients (aged 50-75 years) with eGFR ≥30 mL/min/1.73 m(2) were randomly allocated

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

7. Efficacy of fenofibric Acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia

Efficacy of fenofibric Acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia 21247520 2011 03 07 2011 06 03 2013 11 21 1879-1913 107 6 2011 Mar 15 The American journal of cardiology Am. J. Cardiol. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia. 898-905 10.1016/j.amjcard.2010.11.009 The combination of fibrate and statin therapies may be a treatment option for women with multiple lipid (...) abnormalities. We, therefore, initiated the present safety and efficacy analysis to address the paucity of such data in women with mixed dyslipidemia. A total of 1,393 women with mixed dyslipidemia (low-density lipoprotein [LDL] cholesterol ≥ 130 mg/dl, triglycerides [TG] ≥ 150 mg/dl, high-density lipoprotein [HDL] cholesterol <50 mg/dl), who had enrolled in any 1 of 3 randomized clinical trials, were evaluated. The eligible women were randomized to receive fenofibric acid plus a low- or moderate-dose

EvidenceUpdates2011

8. Pravafenix - fenofibrate / pravastatin

Pravafenix - fenofibrate / pravastatin 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 8613 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union Assessment report for PRAVAFENIX International nonproprietary name: fenofibrate / pravastatin Procedure No. EMEA/H/C/001243 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted Pravafenix CHMP (...) achievement of lipid control in mixed dyslipidaemia usually requires progressive treatment: diet and exercise, followed by pharmacological intervention with an HMG CoA reductase (statins) in monotherapy, subsequently with statins in combination with niacin or fibrates. Pravafenix 40/160 mg is a fixed dose combination (FDC) of pravastatin and fenofibrate formulated as hard capsules. Only one fixed dose combination containing 160 mg fenofibrate and 40 mg pravastatin is claimed. Fenofibrate is a fibric acid

European Medicines Agency - EPARs2011

9. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy

Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy 20816118 2010 09 06 2010 09 28 2013 11 21 1879-1913 106 6 2010 Sep 15 The American journal of cardiology Am. J. Cardiol. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy. 787-92 10.1016/j.amjcard.2010.05.005 Patients with mixed hyperlipidemia and at high (...) risk of coronary heart disease may not achieve recommended low-density lipoprotein (LDL) and non-high-density lipoprotein (non-HDL) cholesterol goals on statin monotherapy. This study was designed to evaluate the efficacy and safety of a fenofibrate 160 mg/pravastatin 40 mg fixed-dose combination therapy in high-risk patients not at their LDL cholesterol goal on pravastatin 40 mg. In this 12-week, multicenter, randomized, double-blind, double-dummy, parallel-group study, after a run

EvidenceUpdates2010

10. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study 19797259 2010 01 04 2011 01 11 2013 11 21 1522-9645 31 1 2010 Jan European heart journal Eur. Heart J. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study (...) . 92-9 10.1093/eurheartj/ehp377 To determine the incidence and predictors of, and effects of fenofibrate on silent myocardial infarction (MI) in a large contemporary cohort of patients with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Routine electrocardiograms taken throughout the study were assessed by Minnesota-code criteria for the presence of new Q-waves without clinical presentation and analysed with blinding to treatment allocation

EvidenceUpdates2010

11. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia

Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia 19195513 2009 02 06 2009 03 19 2015 11 19 1879-1913 103 4 2009 Feb 15 The American journal of cardiology Am. J. Cardiol. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. 515-22 10.1016/j.amjcard.2008.10.025 In patients with mixed dyslipidemia characterized by increased triglycerides (TG), decreased (...) high-density lipoprotein (HDL) cholesterol, and increased low-density lipoprotein (LDL) cholesterol, monotherapy with lipid-altering drugs often fails to achieve all lipid targets. This multicenter, double-blind, active-controlled study evaluated ABT-335 (fenofibric acid) in combination with 2 doses of atorvastatin in patients with mixed dyslipidemia. A total of 613 patients with LDL cholesterol > or =130 mg/dl, TG > or =150 mg/dl, and HDL cholesterol <40 mg/dl for men and <50 mg/dl for women were randomly assigned

EvidenceUpdates2009

12. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. 19465233 2009 05 25 2009 06 08 2017 02 20 1474-547X 373 9677 2009 May 23 Lancet (London, England) Lancet Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. 1780-8 10.1016/S0140-6736(09)60698-X Amputations in people with type 2 diabetes (...) mellitus substantially impair their quality of life and impose high costs on health-care systems. Our aim was to assess the effect of fenofibrate on amputation events in a large cohort of patients with type 2 diabetes. In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, 9795 patients aged 50-75 years with type 2 diabetes were randomly assigned by computer-generated randomisation sequence to receive fenofibrate 200 mg per day (n=4895) or matching placebo (n=4900) for 5 years

Lancet2009 Full Text: Link to full Text with Trip Pro

13. Long term fenofibrate did not reduce major coronary events but may reduce total CVD events in type 2 diabetes

Long term fenofibrate did not reduce major coronary events but may reduce total CVD events in type 2 diabetes Long term fenofibrate did not reduce major coronary events but may reduce total CVD events in type 2 diabetes | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Long term fenofibrate did not reduce major coronary events but may reduce total CVD events in type 2 diabetes Article Text Therapeutics Long term fenofibrate did not reduce major coronary events but may reduce total CVD events in type 2 diabetes Statistics from Altmetric.com No Altmetric data

Evidence-Based Medicine (Requires free registration)2007

14. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. 17988728 2007 11 20 2007 12 06 2015 06 16 1474-547X 370 9600 2007 Nov 17 Lancet (London, England) Lancet Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. 1687-97 Laser treatment for diabetic retinopathy is often associated with visual field reduction and other ocular side-effects. Our aim (...) was to assess whether long-term lipid-lowering therapy with fenofibrate could reduce the progression of retinopathy and the need for laser treatment in patients with type 2 diabetes mellitus. The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study was a multinational randomised trial of 9795 patients aged 50-75 years with type 2 diabetes mellitus. Eligible patients were randomly assigned to receive fenofibrate 200 mg/day (n=4895) or matching placebo (n=4900). At each clinic visit

Lancet2007

15. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. 16310551 2005 11 28 2005 12 15 2015 06 16 1474-547X 366 9500 2005 Nov 26 Lancet (London, England) Lancet Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. 1849-61 Patients with type 2 diabetes mellitus are at increased risk (...) of cardiovascular disease, partly owing to dyslipidaemia, which can be amenable to fibrate therapy. We designed the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study to assess the effect of fenofibrate on cardiovascular disease events in these patients. We did a multinational, randomised controlled trial with 9795 participants aged 50-75 years, with type 2 diabetes mellitus, and not taking statin therapy at study entry. After a placebo and a fenofibrate run-in phase, we randomly assigned

Lancet2005

16. Pharmacoeconomic evaluation of anti-hyperlipidemic agent fenofibrate

Pharmacoeconomic evaluation of anti-hyperlipidemic agent fenofibrate Pharmacoeconomic evaluation of anti-hyperlipidemic agent fenofibrate Pharmacoeconomic evaluation of anti-hyperlipidemic agent fenofibrate Hayakawa T, Shimoyama K, Sekiya S, Sekiguchi M, Inotsume N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology Fenofibrate was given to patients with type IIb or type IV hyperlipidemia who had previously been taking either bezafibrate or a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (HMG-CoA RI). Fenofibrate doses varied from 100-200mg/day. Bezafibrate doses varied from 200-400mg/day. The pravastatin dose was 10mg/day, the simvastatin dose was 5mg/day and the fluvastatin dose was 20mg/day. The study compared

NHS Economic Evaluation Database.2002

17. Effects of fenofibrate and gemfibrozil on plasma homocysteine.

Effects of fenofibrate and gemfibrozil on plasma homocysteine. 11454380 2001 07 16 2001 07 26 2015 06 16 0140-6736 358 9275 2001 Jul 07 Lancet (London, England) Lancet Effects of fenofibrate and gemfibrozil on plasma homocysteine. 39-40 Fenofibrate increases plasma homocysteine. Because the concentration of plasma homocysteine depends on renal function, we postulate that increases in plasma homocysteine are a result of the known impairment of renal function caused by fenofibrate. Gemfibrozil (...) , another fibrate, does not affect renal function. In a crossover study we tested whether gemfibrozil would raise homocysteine. 22 patients who had hypertriglyceridaemia were given 900 mg gemfibrozil or 200 mg fenofibrate daily for 6 weeks. Lipids were altered similarly, but homocysteine, creatinine, and cystatin C were raised by fenofibrate but not by gemfibrozil (p for differences between treatment effects: 0.007, 0.006, and 0.040, respectively). We propose gemfibrozil should be the fibrate of choice

Lancet2001

18. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. 11289345 2001 04 05 2001 04 19 2015 06 16 0140-6736 357 9260 2001 Mar 24 Lancet (London, England) Lancet Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. 905-10 Atherosclerosis is the most common complication of diabetes. Correction (...) with type 2 diabetes were screened by metabolic and angiographic criteria. 418 were randomly assigned micronised fenofibrate (200 mg/day) or placebo for at least 3 years. They were in good glycaemic control (mean haemoglobin A1c 7.5%), had mild lipoprotein abnormalities, typical of type 2 diabetes, and at least one visible coronary lesion. Half had no previous clinical coronary disease. Initial and final angiograms followed a standard protocol and were analysed by a computer-assisted quantitative approach. Missing

Lancet2001

19. Micronized fenofibrate: a new fibric acid hypolipidemic agent

Micronized fenofibrate: a new fibric acid hypolipidemic agent Micronized fenofibrate: a new fibric acid hypolipidemic agent Micronized fenofibrate: a new fibric acid hypolipidemic agent Guay D R Authors' objectives To assess the efficacy and safety of fenofibrate in the management of hyperlipidaemias. Searching MEDLINE (from 1974 to October 1998) and Currents Contents were searched, and the bibliographies from identified studies were examined. In addition, the package inserts from (...) the manufacturers were used to identify data. Study selection Study designs of evaluations included in the review The inclusion criteria were not defined in terms of study design. The studies included were randomised controlled trials (RCTs) of parallel or crossover design, including double-blinded RCTs, and observational studies. The duration of the comparative studies ranged from 4 weeks to 1 year. Specific interventions included in the review Studies evaluating fenofibrate were eligible. Fenofibrate (regular

DARE.1999

20. Serum homocysteine increases after therapy with fenofibrate or bezafibrate.

Serum homocysteine increases after therapy with fenofibrate or bezafibrate. 10421307 1999 08 10 1999 08 10 2015 11 19 0140-6736 354 9174 1999 Jul 17 Lancet (London, England) Lancet Serum homocysteine increases after therapy with fenofibrate or bezafibrate. 219-20 A 44% and 17.5% increase of homocysteine occurred in patients treated either with fenofibrate or bezafibrate. The increase was not explained by changes in vitamin concentrations but may be related to renal function. Dierkes J J (...) Westphal S S Luley C C eng Clinical Trial Comparative Study Letter Randomized Controlled Trial England Lancet 2985213R 0140-6736 0 Hematinics 0 Hypolipidemic Agents 0LVT1QZ0BA Homocysteine 935E97BOY8 Folic Acid KV2JZ1BI6Z Pyridoxine P6YC3EG204 Vitamin B 12 U202363UOS Fenofibrate Y9449Q51XH Bezafibrate AIM IM Lancet. 2000 Jun 24;355(9222):2249-50 10881914 Lancet. 1999 Oct 2;354(9185):1209 10513738 Lancet. 1999 Oct 2;354(9185):1208-9 10513737 Lancet. 1999 Oct 2;354(9185):1208 10513736 Adult Bezafibrate

Lancet1999